Coming Soon

  • Study shows Chronix Biomedical liquid biopsy was 91% accurate at distinguishing patients with prostate cancer from patients with other medical conditions that may be associated with a higher PSA levels (e.g. Prostatitis or benign Prostate hyperplasia).
  • There are approximately 1.2 million prostate biopsies a year in the US due to elevated PSA. Only 20% are found to be true cancer, almost 1 million biopsies were without any indication of a malignancy.
  • Reducing unnecessary biopsies could reduce the $12 billion in estimated annual spending related to prostate cancer.
  • Chronix Biomedical soon will be offering the first of its kind liquid biopsy test to aid doctors in their decision making whether patients with marginally elevated PSA would benefit a tissue biopsy or just being monitored
  • Clinical Chemistry Abstract
  • Clinical Chemistry Podcast
  • Clinical Chemistry Transcript
  • Vanderbilt University News
  • New York Times Article about PSA Testing
Sign up to Learn More


Copyright © 2012 Chronix Biomedical, Inc. All rights reserved.
made by Vento